Evaluation and improvement of the pharmacokinetics, biodistribution and stability of fibronectin-derived binding proteins (monobodies)

In my work, I have provided primary insight into the pharmacological properties and stability of monobodies and demonstrated a facile way to improve not only their in vivo-properties but also plasma stability in vitro through fusion to an albumin binding domain. The resulting albumin binding domain-monobodies (ABD-Mb) retained binding capability to their primary target at low nanomolar affinity and bound effectively to human and mouse albumin. Additionally, ABD-monobodies exhibited prolonged in vitro-plasma stability and the in vivo-circulation time of ABD-AS25 in mice was significantly increased by 92-fold, compared to wildtype AS25, with the majority of the ABD-monobody remaining in the bloodstream, while the wildtype monobody was cleared through the kidneys within minutes after application. By addition of a third binding moiety against surface targets like PD-L1, EGFR and HER2, whose deregulation is commonly associated with cancer, I created trifunctional monobodies with the ability to specifically bind cells expressing the respective target at high levels, without perturbing the binding of the initial monobody or the albumin binding domain. Since our laboratory has developed monobodies to target intracellular oncogenes, I further investigated the degradation kinetics and mechanism of monobodies upon their Doxycycline-induced intracellular expression, showing that intracellular levels of HA4-YA monobody in HeLa, A549 or Baf3 p210 cells declined rapidly within the first 24 hours after Doxycycline was withdrawn. This decline was partially prevented by inhibition of the ubiquitin proteasome pathway by Bortezomib, indicating this pathway to play a major role in the degradation of intracellular monobodies. Consequently, I have exchanged the tags and mutated lysine-residues of intracellular monobodies to prevent ubiquitination, the first critical step in the course of proteasomal degradation.

Publication Details

Journal
data_UMR
Published
2025-03-13
DOI
https://doi.org/10.17192/z2025.0161
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation and improvement of the pharmacokinetics, biodistribution and stability of fibronectin-derived binding proteins (monobodies)

data_UMR
Monoclonal and Polyclonal Antibodies Research
article

Evaluation and improvement of the pharmacokinetics, biodistribution and stability of fibronectin-derived binding proteins (monobodies)

article en

Abstract

In my work, I have provided primary insight into the pharmacological properties and stability of monobodies and demonstrated a facile way to improve not only their in vivo-properties but also plasma stability in vitro through fusion to an albumin binding domain. The resulting albumin binding domain-monobodies (ABD-Mb) retained binding capability to their primary target at low nanomolar affinity and bound effectively to human and mouse albumin. Additionally, ABD-monobodies exhibited prolonged in vitro-plasma stability and the in vivo-circulation time of ABD-AS25 in mice was significantly increased by 92-fold, compared to wildtype AS25, with the majority of the ABD-monobody remaining in the bloodstream, while the wildtype monobody was cleared through the kidneys within minutes after application. By addition of a third binding moiety against surface targets like PD-L1, EGFR and HER2, whose deregulation is commonly associated with cancer, I created trifunctional monobodies with the ability to specifically bind cells expressing the respective target at high levels, without perturbing the binding of the initial monobody or the albumin binding domain. Since our laboratory has developed monobodies to target intracellular oncogenes, I further investigated the degradation kinetics and mechanism of monobodies upon their Doxycycline-induced intracellular expression, showing that intracellular levels of HA4-YA monobody in HeLa, A549 or Baf3 p210 cells declined rapidly within the first 24 hours after Doxycycline was withdrawn. This decline was partially prevented by inhibition of the ubiquitin proteasome pathway by Bortezomib, indicating this pathway to play a major role in the degradation of intracellular monobodies. Consequently, I have exchanged the tags and mutated lysine-residues of intracellular monobodies to prevent ubiquitination, the first critical step in the course of proteasomal degradation.

data_UMR
Openalex Percentile: Top 43%
Monoclonal and Polyclonal Antibodies Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Evaluation and improvement of the pharmacokinetics, biodistribution and stability of fibronectin-derived binding proteins (monobodies) · data_UMR (2025) | TGRS Research Map | TGRS